Bioage Labs vs Opus Genetics
Opus Genetics is the larger business, with $14.2m of revenue in fiscal 2025 against $9.0m for Bioage Labs (1.6 times as much). Opus Genetics kept more of each dollar of sales as profit: a net margin of -349.3% against -896.1%. Bioage Labs carries less debt relative to equity (1.0% against 7.4%).
| Latest fiscal year | Bioage LabsBIOA, 2025 | Opus GeneticsIRD, 2025 |
|---|---|---|
| Revenue | $9.0m | $14.2m |
| Revenue growth | — | 29.1% |
| Net income | −$80.6m | −$49.6m |
| Operating margin | -1031.5% | -271.9% |
| Net margin | -896.1% | -349.3% |
| Return on equity | -27.1% | — |
| Free cash flow | −$82.3m | −$35.3m |
| Cash | $189m | $45.1m |
| Total debt | $2.6m | $1.1m |
| Debt to equity | 1.0% | 7.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 62 | 27 |
| Market value | $266m | $306m |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 13 sales | 2 buys, 23 sales |